Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1No longer available 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 3Sarcoma 2Pancreatic Neoplasms 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Pleural Effusion, Malignant 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Vincristine 2Temozolomide 2Irinotecan 2Doxorubicin 2Cyclophosphamide 2Bone Marrow Transplantation 2robatumumab 1pegfilgrastim 1palbociclib 1lexatumumab 1ganitumab 1disaccharide tripeptide 1delta 24-sterol reductase 1copanlisib 1bempegaldesleukin 1Thiotepa 1Radiosurgery 1Plicamycin 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Melphalan 1Magnetic Resonance Spectroscopy 1Interferon-gamma 1Immunotherapy, Adoptive 1INCB059872 1IL32 protein, human 1Granulocyte Colony-Stimulating Factor 1Genistein 1Filgrastim 1FANG vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sarcoma, Ewing × ganitumab × Clear all
NCT04129151 2024-08-01

Palbociclib + Ganitumab In Ewing Sarcoma

Dana-Farber Cancer Institute

Phase 2 Terminated
10 enrolled 15 charts
Sarcoma

Recurrence, Sarcoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡